尼莫地平联合高压氧治疗急性脑梗死的临床观察  被引量:1

Efficacy Observation of Nimodipine Combined with Hyperbaric Oxygen in the Treatment of Acute Cerebral Infarction

在线阅读下载全文

作  者:于维颖[1] 秦红梅[1] 冀红[1] 宋怡[1] 

机构地区:[1]大连医科大学附属第一医院,辽宁大连116011

出  处:《中国药房》2013年第48期4549-4551,共3页China Pharmacy

摘  要:目的:观察尼莫地平联合高压氧(HBO)治疗急性脑梗死的疗效及安全性。方法:将178例急性脑梗死患者随机分成两组,对照组88例,试验组90例。在常规药物治疗基础上,对照组患者每天早、晚两次静脉滴注尼莫地平(以10 mg加入5%葡萄糖注射液500 ml中);试验组患者给予尼莫地平的同时每天进行HBO治疗1次。两组患者均连续治疗14 d。观察两组患者的临床疗效、神经功能缺损评分以及不良反应发生率。结果:治疗后试验组患者的总有效率(91.11%)显著高于对照组(78.41%),神经功能缺损评分显著低于对照组,两组比较差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:尼莫地平联合HBO治疗急性脑梗死较单纯应用尼莫地平治疗疗效更显著,且安全性相当。OBJECTIVE: To observe clinical efficacy and safety of nimodipine combined with hyperbaric oxygen (HBO) for acute cerebral infarction. METHODS: 178 patients with acute cerebral infarction were randomly divided into 2 groups, 88 cases in control group and 90 cases in trial group. Based on conventional treatment, control group was given intravenous drip of nimodipine morning and night (10 mg added into 5% Glucose injection 500 ml, i.v. gtt); trial group was additionally given HBO once a day based on control group. Treatment course of both groups lasted for consecutive 14 days. The clinical efficacies of both groups were observed and compared, as well as nerve function defect score and the incidence of ADR. RESULTS: Total effective rate of trial group (91.11% ) was higher than that of control group (78.41% ), and the nerve function defect score of trial group was significantly lower than that of control group after treatment, there was statistical significance(P〈0.05). There was no statistical significance in the incidence of ADR between 2 groups(P〉0.05). CONCLUSIONS: Nimodipine combined with HBO is better than nimodipine alone in the treatment of acute cerebral infarction with good safety.

关 键 词:高压氧 尼莫地平 急性脑梗死 疗效 安全性 

分 类 号:R743.33[医药卫生—神经病学与精神病学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象